Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB announced an investor meeting to update stakeholders on the progress of their drug candidate, arfolitixorin, which is undergoing a phase Ib/II clinical study at Charité – Universitätsmedizin Berlin. This meeting, scheduled for November 13, 2025, will provide insights into the potential of arfolitixorin to address treatment gaps in cancer care, with opportunities for participants to engage in discussions both in-person and online.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on enhancing cancer treatment efficacy. Their primary product, arfolitixorin, is a clinical-stage drug candidate aimed at improving the effectiveness of standard treatments for solid tumors, particularly colorectal cancer.
Average Trading Volume: 718,474
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK196.1M
See more data about ISOFOL stock on TipRanks’ Stock Analysis page.